Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis

  • Shusuke Numata1Email author,
  • Makoto Kinoshita1,
  • Atsushi Tajima2, 3,
  • Akira Nishi1,
  • Issei Imoto3 and
  • Tetsuro Ohmori1
BMC Medical Genetics201516:54

https://doi.org/10.1186/s12881-015-0197-7

Received: 11 November 2014

Accepted: 3 July 2015

Published: 26 July 2015

Abstract

Background

The results of meta-analyses conducted by previous association studies between total homocysteine and schizophrenia suggest that an elevated total homocysteine level is a risk factor for schizophrenia. However, observational studies have potential limitations, such as confounding and reverse causation. In the present study, we evaluated a causal relationship between plasma total homocysteine and schizophrenia by conducting a Mendelian randomization analysis.

Methods

We used the MTHFR C677T polymorphism as an instrumental variable, which affects the plasma total homocysteine levels. To calculate the risk estimate for the association of this single nucleotide polymorphism (SNP) with schizophrenia, we conducted a meta-analysis of case–control studies that comprise a total of 11,042 patients with schizophrenia and 14,557 control subjects. We obtained an estimate for the association of this SNP with the plasma total homocysteine levels from a meta-analysis of genome-wide association studies comprising 44,147 individuals.

Results

By combining these two estimates, we demonstrated a significant effect of the plasma total homocysteine on schizophrenia risk, representing an OR of 2.15 (95 % CI = 1.39–3.32; p = 5.3 x 10−4) for schizophrenia per 1-SD increase in the natural log-transformed plasma total homocysteine levels.

Conclusions

We provided evidence of a causal relationship between the plasma total homocysteine and schizophrenia, and this result will add insight into the pathology and treatment of schizophrenia.

Background

Homocysteine is a key substance in the methionine cycle, which is involved in one-carbon methyl group-transfer metabolism. The methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133) polymorphism is a well-characterized genetic variant. C677T of the MTHFR gene results in amino-acid substitution (Ala222Val), and causes a reduction of enzyme activity and higher plasma total homocysteine levels [1]. The association of this variant with the plasma total homocysteine was confirmed by a recent meta-analysis of genome-wide association studies [2]. Previous meta-analyses of association studies between total homocysteine, which includes plasma and serum total homocysteine, and schizophrenia suggest that an elevated total homocysteine level is a risk factor for schizophrenia [3, 4]. However, observational studies have potential limitations, such as confounding, reverse causation, and selection bias. In fact, several findings of observational studies have been shown to be spurious causes by subsequent randomized controlled trials, such as hormone replacement therapy in coronary heart disease, β carotene in lung cancer, and vitamin E and vitamin C in cardiovascular disease [5]. In addition to genetic variants [2], many determinants that affect plasma total homocysteine concentrations, including physiologic determinants, such as age and sex, lifestyle determinants, such as vitamin intake, smoking and coffee, and clinical conditions, such as folate deficiency and renal failure, have been reported [6]. Moreover, whether hyper-homocysteine itself causes schizophrenia or schizophrenia causes hyper-homocysteine has not been clarfied. For examples, the high prevalence of smoking and decreased folate levels in patients with schizophrenia have been reported [710], both of which are known to be associated with increased plasma total homocysteine concentrations.

Mendelian randomization analysis, which uses genetic variants as instrumental variables for exposures of interest, can overcome problems of confounding and reverse causality, and is a useful method for assessing causal relationships in epidemiological studies [1116].

Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. A specific genotype carried by a person results from two such randomized transmission, one from the paternally inherited allele and the other from the maternally allele. As a consequence of these randomizations, genotypes are not expected to be associated with known or unknown confounders for any outcome of interest, except those lying on the causal pathway between the genotype and the outcome. This allows analyzing the genotype-risks factor association (in this case, the genotype-the plasma total homocysteine) and the genotype-outcome association (in this case, the genotype-schizophrenia) in an unconfounded manner [13]. By combining the results of the genotype-risk factor association and the genotype-outcome association, one can get an estimate of the risk factor-outcome association (in this case, the plasma total homocysteine-schizophrenia). In addition, genetic variants are equivalent to lifetime differences in risk factor (in this case, the plasma total homocysteine), and indicate the long term effects of risk factor on disease (in this case, schizophrenia). They therefore generate more realistic estimates of causal effects between risk factor and disease [5]. The Mendelian randomization approach has similar properties to the analysis of the intention to treat in randomized controlled trials [5, 17], and this approach has provided new insights into the pathology of several diseases, such as cardiovascular disease, diabetes, and Parkinson disease [1826].

In this study, we evaluated a causal relationship between plasma total homocysteine and schizophrenia by conducting a Mendelian randomization analysis based on the MTHFR C677T polymorphism as an instrumental variable.

Methods

The estimate for gene-schizophrenia association

The risk estimate for the gene-schizophrenia association of the T allele of the MTHFR C677T polymorphism (OR scz/per T-allele) was evaluated by conducting a meta-analysis of case–control studies with the random-effect model by ‘metafor’, an R package. Eligible studies were identified using SZGene [27] and the PubMed search engine with the terms “Methylenetetrahydrofolate reductase” or “MTHFR” or “schizophrenia”. We also conducted an additional manual search of reference lists and review articles. Studies meeting the following criteria were included for meta-analysis: (1) performed a case–control study (i.e., schizophrenia versus control), (2) provided data on genotype frequencies, and (3) was published in the English language. The two reviewers (Kinoshita M and Nishi A) selected the articles independently according to the above inclusion criteria, and then discussed the articles until they reached a consensus on every study used for the meta-analysis. Heterogeneity was assessed using the I2 statistic, and publication bias was assessed using funnel plots and a regression test [28]. OR and 95 % confidence intervals (CI) were calculated by ‘metafor’, an R package. Finally, we used 36 case–control studies from 32 papers for a total of 11,042 patients with schizophrenia and 14,557 control subjects [4, 2959] based on a Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) flowchart [60] (Additional file 1: Figure S1).

The estimate for gene-plasma total homocysteine association

We used a pooled estimate of per-T allele standardized β coefficient (0.158) of the effect of the MTHFR C677T polymorphism on the natural log-transformed plasma total homocysteine levels (beta hcy/per T-allele) from a recent meta-analysis of genome-wide association studies comprising 44,147 individuals [2].

Mendelian randomization analysis

We calculated a Mendelian randomization estimate of the effect of the plasma total homocysteine levels on the risk of schizophrenia (OR scz/hcy) as log OR scz/hcy = (log OR scz/per T-allele)/ beta hcy/per T-allele, as in previous studies [4, 21]. Log OR scz/hcy is the (log) increase of schizophrenia risk by 1-standard deviation (SD) increase in the natural log-transformed plasma total homocysteine (plasma total homocysteine-schizophrenia association). Log OR scz/per T-allele is the (log) increase in schizophrenia risk per T allele of the MTHFR C677T polymorphism (gene-schizophrenia association). Beta hcy/per T-allele is the number of SD differences in the natural log-transformed plasma total homocysteine levels per the T allele (SD/allele) (gene-plasma total homocysteine association).

Results

The pooled OR scz/per T-allele was 1.13 (95 % CI = 1.06–1.22; p = 5.9 x 10−4 in the random-effects model) with significant heterogeneity (I2 = 66.1 %; p < 0.05; Fig. 1). The funnel plot analysis indicated no evidence of publication bias in this meta-analysis (p > 0.05). By combining two pooled estimates, OR scz/per T-allele from a meta-analysis of 36 case–control studies and beta hcy/per T-allele from a meta-analysis of genome-wide association studies by van Meurs and colleagues [2], we found a significant effect of the plasma total homocysteine on schizophrenia risk in the Mendelian randomization analysis, representing an OR scz/hcy of 2.15 (95 % CI = 1.39–3.32; p = 5.3 x 10−4) for schizophrenia per 1-SD increase in the natural log-transformed plasma total homocysteine levels (Fig. 2).
Fig. 1

A meta-analysis of genetic association studies between the MTHFR C677T polymorphism and schizophrenia. Thirty six case–control studies were used for the meta-analysis (N = 25,599). The pooled OR per T allele of the MTHFR C677T polymorphism on schizophrenia risk was 1.13 (95 % CI = 1.06–1.22; p = 5.9 x 10−4) in the random-effects model with significant heterogeneity among studies (I2 = 66.1 %; p < 0.05)

Fig. 2

Graphical representation of the Mendelian randomization approach. The risk estimate for the gene-schizophrenia association of the T allele of the MTHFR C677T polymorphism was obtained from the present meta-analysis of previous genetic association studies that cover a total of 25,599 individuals (11,042 cases and 14,557 controls). To establish the gene-homocysteine association, we took a pooled estimate of the effect of the MTHFR C677T polymorphism on the plasma total homocysteine levels from a recent meta-analysis of previous genome-wide association studies, including 44,147 individuals (van Meurs et al. [2]). From these two estimates, we calculated a Mendelian randomization estimate of the effect of the plasma total homocysteine levels on the risk of schizophrenia. This estimate represented the OR for schizophrenia risk per 1-SD increase in the log-transformed plasma total homocysteine levels

Discussion

By conducting a Mendelian randomization approach, we demonstrated that increased plasma total homocysteine concentration levels may be causally associated with an increased risk of developing schizophrenia. Our finding is consistent with the result of our recent paper that used a Japanese cohort [4]. Our finding is also supported by a longitudinal study in which elevated maternal levels of homocysteine levels during the third trimester were found to increase the risk of schizophrenia in the offspring [61]. Furthermore, the benefits of homocysteine-reducing strategies in schizophrenia have been reported in previous studies with randomized, double-blind, and placebo-controlled designs. Levine et al. [62] reported an improvement in the clinical symptoms of the patients with schizophrenia and hyper-homocysteinemia (over 15umol/L) who were treated with folate, vitamin B12, and pyridoxine. Roffman et al. [63] reported an improvement in the negative symptoms of patients with schizophrenia who were treated with folate and vitamin B12 when several functional genetic variants were taken into account.

Hyper-homocysteine has also been observed in cardiovascular disease [64], and yet randomized trials have failed to demonstrate benefit of homocysteine-lowering intervention on cardiovascular outcomes [18, 65]. The discordant results from observational studies and randomized trials might be caused by the limited period of the randomized trials, the effects of aspirin and other antiplatelet drugs [66], confounding factors, or reverse causation. Several papers had not found evidence in support of a causal association between homocysteine and cardiovascular disease [2, 18].

There are some limitations to the present Mendelian randomization analysis. One is the number of genetic variants. We used one polymorphism as the instrumental variable that affects the plasma total homocysteine concentrations. However, a recent meta-analysis of genome wide association studies of the plasma total homocysteine has identified several genetic variants [2]. Further replication studies will be needed using multiple genetic variants related to the plasma total homocysteine levels, because using multiple instruments increases the precision of the instrumental variable estimates [14]. The second is a reintroduced confounding through pleiotropy [12, 14, 15]. Pleiotropy is defined as the phenomenon in which a single locus affects two or more distinct phenotypic traits [67]. The MTHFR C677T polymorphism may directly influence more than one post-transcriptional process. The third is population stratification [12, 14, 15]. When we estimated both gene-schizophrenia association and gene-plasma total homocysteine association, we used a cohort that was composed of a mixed population. The fourth is a developmental compensation [12, 15]. During development, compensatory process may be generated that counter the phenotypic perturbation consequent on the genetic variant utilized as an instrument [15].

Conclusions

In summary, we provided evidence of a causal relationship between the plasma total homocysteine and schizophrenia by conducting a Mendelian randomization approach. However, our findings have to be interpreted with caution because of the limitations, such as pleiotropy and population stratification.

Funding body agreements and policies

This work was supported in part by Japan Science and Technology Agency, CREST and a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (grant number 24791216 and 26860931), SENSHIN Medical Research Foundation, and the Research Group for Schizophrenia.

Declarations

Acknowledgments

Mrs. Okada A assisted with the preparation of experiments and provided the data necessary for our analysis.

Authors’ Affiliations

(1)
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School
(2)
Department of Bioinformatics and Genomics, Graduate School of Medical Sciences, Kanazawa University
(3)
Department of Human Genetics, Institute of Biomedical Sciences, Tokushima University Graduate School

References

  1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.View ArticlePubMedGoogle Scholar
  2. van Meurs JB, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen SH, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr. 2013;98:668–76.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006;11:143–9.View ArticlePubMedGoogle Scholar
  4. Nishi A, Numata S, Tajima A, Kinoshita M, Kikuch IK, Shimodera S, et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull. 2014;40:1154–63.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Davey SG, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ. 2005;330:1076–9.View ArticleGoogle Scholar
  6. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50:3–32.View ArticlePubMedGoogle Scholar
  7. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143:993–7.View ArticlePubMedGoogle Scholar
  8. Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J Nerv Ment Dis. 2002;190:604–10.View ArticlePubMedGoogle Scholar
  9. Saedisomeolia A, Djalali M, Moghadam AM, Ramezankhani O, Najmi L. Folate and vitamin B12 status in schizophrenic patients. J Res Med Sci. 2011;16 Suppl 1:S437–41.PubMedPubMed CentralGoogle Scholar
  10. Song X, Fan X, Li X, Kennedy D, Pang L, Quan M, et al. Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophr Res. 2014;159:51–5.View ArticlePubMedGoogle Scholar
  11. Davey SG, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.View ArticleGoogle Scholar
  12. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63.View ArticlePubMedGoogle Scholar
  13. Bochud M, Rousson V. Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health. 2010;7:711–28.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobia JH, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 2012;21:223–42.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Davey SG, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89–98.View ArticleGoogle Scholar
  16. Taylor AE, Davies NM, Ware JJ, VanderWeele T, Smith GD, Munafò MR. Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates. Econ Hum Biol. 2014;13:99–106.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Thanassoulis G. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease. Can J Cardiol. 2013;29:30–6.View ArticlePubMedGoogle Scholar
  18. Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, et al. MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case–control studies, avoiding publication bias. PLoS Med. 2012;9:e1001177.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–80.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Palmer TM, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Davey SG, Lawlor DA, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f4262.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Pichler I, Del Grec MF, Gögele M, Lill CM, Bertram L, Do CB, et al. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med. 2013;10:e1001462.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Yaghootkar H, Lamina C, Scott RA, Dastani Z, Hivert MF, Warren LL, et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes. 2013;62:3589–98.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2014. [Epub ahead of print].Google Scholar
  24. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94:198–208.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Soave D, Miller MR, Keenan K, Li W, Gong J, Ip W, et al. Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study. Diabetes. 2014;63:2114–9.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40:827–34.View ArticlePubMedGoogle Scholar
  28. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguch IH, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet. 1997;74:526–8.View ArticlePubMedGoogle Scholar
  30. Kunugi H, Fukuda R, Hattori M, Kato T, Tatsumi M, Sakai T, et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psychiatry. 1998;3:435–7.View ArticlePubMedGoogle Scholar
  31. Joober R, Benkelfat C, Lal S, Bloom D, Labelle A, Lalonde P, et al. Association between the methylenetetrahydrofolate reductase 677C > T missense mutation and schizophrenia. Mol Psychiatry. 2000;5:323–6.View ArticlePubMedGoogle Scholar
  32. Sazci A, Ergül E, Güzelhan Y, Kaya G, Kara I. Methylenetetrahydrofolate reductase gene polymorphisms in patients with schizophrenia. Brain Res Mol Brain Res. 2003;117:104–7.View ArticlePubMedGoogle Scholar
  33. Tan EC, Chong SA, Lim LC, Chan AO, Teo YY, Tan CH, et al. Genetic analysis of the thermolabile methylenetetrahydrofolate reductase variant in schizophrenia and mood disorders. Psychiatr Genet. 2004;14:227–31.View ArticlePubMedGoogle Scholar
  34. Yu L, Li T, Robertson Z, Dean J, Gu NF, Feng GY, et al. No association between polymorphisms of methylenetetrahydrofolate reductase gene and schizophrenia in both Chinese and Scottish populations. Mol Psychiatry. 2004;9:1063–5.View ArticlePubMedGoogle Scholar
  35. Muntjewerff JW, Hoogendoorn ML, Kahn RS, Sinke RJ, Den Heijer M, Kluijtmans LA, et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case–control study. Am J Med Genet B Neuropsychiatr Genet. 2005;135B:69–72.View ArticlePubMedGoogle Scholar
  36. Sazci A, Ergul E, Kucukali I, Kara I, Kaya G. Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: association is significant in men but not in women. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1113–23.View ArticlePubMedGoogle Scholar
  37. Vilella E, Virgos C, Murphy M, Martorell L, Valero J, Simó JM, et al. Further evidence that hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1169–74.View ArticlePubMedGoogle Scholar
  38. Kempisty B, Mostowska A, Górska I, Łuczak M, Czerski P, Szczepankiewicz A, et al. Association of 677C > T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. Neurosci Lett. 2006;400:267–71.View ArticlePubMedGoogle Scholar
  39. Lee YS, Han DH, Jeon CM, Lyoo IK, Na C, Chae SL, et al. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. Neuroreport. 2006;17:743–6.View ArticlePubMedGoogle Scholar
  40. Philibert R, Gunter T, Hollenbeck N, Adams WJ, Bohle P, Packer H, et al. No association of the C677T methylenetetrahydrofolate reductase polymorphism with schizophrenia. Psychiatr Genet. 2006;16:221–3.View ArticlePubMedGoogle Scholar
  41. Jönsson EG, Larsson K, Vares M, Hansen T, Wang AG, Djurovic S, et al. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:976–82.View ArticlePubMedGoogle Scholar
  42. Roffman JL, Gollub RL, Calhoun VD, Wassin TH, Weiss AP, Ho BC, et al. MTHFR 677C > T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val > Met. Proc Natl Acad Sci U S A. 2008;105:17573–8.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Betcheva ET, Mushiroda T, Takahashi A, Kubo M, Karachanak SK, Zaharieva IT, et al. Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population. J Hum Genet. 2009;54:98–107.View ArticlePubMedGoogle Scholar
  44. Feng LG, Song ZW, Xin F, Hu J. Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: A Chinese Han population-based case–control study. Psychiatry Res. 2009;168:205–8.View ArticlePubMedGoogle Scholar
  45. Bouaziz N, Ayedi I, Sidhom O, Kallel A, Rafrafi R, Jomaa R, et al. Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res. 2010;2010(179):24–9.View ArticleGoogle Scholar
  46. García-Miss Mdel R, Pérez-Mutul J, López-Canul B, Solís-Rodríguez F, Puga-Machado L, Oxté-Cabrera A, et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res. 2010;44:441–6.View ArticlePubMedGoogle Scholar
  47. Kang HJ, Choe BM, Kim SH, Son SR, Lee KM, Kim BG, et al. No Association Between Functional Polymorphisms in COMT and MTHFR and Schizophrenia Risk in Korean Population. Epidemiol Health. 2010;32:e2010011.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Yoshimi A, Aleksic B, Kawamura Y, Takahashi N, Yamada S, Usui H, et al. Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. Schizophr Res. 2010;124:216–22.View ArticlePubMedGoogle Scholar
  49. Arzaghi SM, Hossein-Nezhad A, Shariat SV, Ghodsipour A, Shams J, Larijani B. C677T Methylenetetrahydrofolate Reductase (MTHFR) Gene Polymorphism in Schizophrenia and Bipolar Disorder: An Association Study in Iranian Population. Iran J Psychiatry. 2011;6:1–6.PubMedPubMed CentralGoogle Scholar
  50. Kim SG, Song JY, Joo EJ, Jeong SH, Kim SH, Lee KY, et al. No association of functional polymorphisms in methlylenetetrahydrofolate reductase and the risk and minor physical anomalies of schizophrenia in Korean population. J Korean Med Sci. 2011;26:1356–163.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Muntjewerff JW, Ophoff RA, Buizer-Voskamp JE, Strengman E, den Heijer M, GROUP Consortium. Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia. Eur Neuropsychopharmacol. 2011;21:300–5.View ArticlePubMedGoogle Scholar
  52. Tsutsumi A, Glatt SJ, Kanazawa T, Kawashige S, Uenishi H, Hokyo A, et al. The genetic validation of heterogeneity in schizophrenia. Behav Brain Funct. 2011;7:43.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Roffman JL, Nitenson AZ, Agam Y, Isom M, Friedman JS, Dyckman KA, et al. A hypomethylating variant of MTHFR, 677C > T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS One. 2011;6:e25253.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Lajin B, Alhaj Sakur A, Michati R, Alachkar A. Association between MTHFR C677T and A1298C, and MTRR A66G polymorphisms and susceptibility to schizophrenia in a Syrian study cohort. Asian J Psychiatr. 2012;5:144–9.View ArticlePubMedGoogle Scholar
  55. El-Hadidy MA, Abdeen HM, Abd El-Aziz SM, Al-Harrass M. C677T Methylenetetrahydrofolate reductase gene polymorphism in schizophrenia and bipolar disorder. Psychiatr Genet. 2013. [Epub ahead of print].Google Scholar
  56. Kontis D, Theochari E, Fryssira H, Kleisas S, Sofocleous C, Andreopoulou A, et al. COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett. 2013;537:17–22.View ArticlePubMedGoogle Scholar
  57. Zhang Y, Yan H, Tian L, Wang F, Lu T, Wang L, et al. Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients. Behav Brain Res. 2013;243:146–52.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Lochman J, Plesník J, Janout V, Povová J, Míšek I, Dvořáková D, et al. Interactive effect of MTHFR and ADRA2A gene polymorphisms on pathogenesis of schizophrenia. Neuro Endocrinol Lett. 2013;34:792–7.PubMedGoogle Scholar
  59. Agam Y, Vangel M, Roffman JL, Gallagher PJ, Chaponis J, Haddad S, et al. Dissociable genetic contributions to error processing: a multimodal neuroimaging study. PLoS One. 2014;9:e101784.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry Jr CP, Liu L, Bresnahan M, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64:31–9.View ArticlePubMedGoogle Scholar
  62. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60:265–9.View ArticlePubMedGoogle Scholar
  63. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70:481–9.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.View ArticlePubMedPubMed CentralGoogle Scholar
  65. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou D-E, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013;1:CD006612.PubMedGoogle Scholar
  66. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One. 2011;6:e16473.View ArticlePubMedPubMed CentralGoogle Scholar
  67. Stearns FW. One hundred years of pleiotropy: a retrospective. Genetics. 2010;186:767–73.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Numata et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement